OBJECTIVES: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). METHODS: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months after start of interferon-beta treatment. RESULTS: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1+/-SD 8.1 years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C (p=0.009) and TC (p=0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse (p=0.006) and the greater number of relapses (p=0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new T2 lesions (p=0.002) and with increased brain atrophy (p<0.001) in patients with high LDL-C. CONCLUSIONS: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.Copyright © 2013.

Weinstock Guttman Bianca Department of Neurology State University of New York Buffalo NY USA

000      

00000naa a2200000 a 4500

001      

bmc18035713

003      

CZ-PrNML

005      

20220411124859.0

007      

ta

008      

181023s2013 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.jneuroim.2013.07.010 $2 doi

035    __

$a (PubMed)23916695

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Weinstock-Guttman B $u Weinstock-Guttman, Bianca. Department of Neurology, State University of New York, Buffalo, NY, USA.

245    10

$a Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes / $c B Weinstock-Guttman, D Horakova, R Zivadinov, M Tamano-Blanco, D Badgett, M Tyblova, M Vaneckova, Z Seidl, J Krasensky, N Bergsland, DP Ramasamy, J Hagemeier, E Havrdova, M Ramanathan

520    9_

$a OBJECTIVES: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). METHODS: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months after start of interferon-beta treatment. RESULTS: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1+/-SD 8.1 years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C (p=0.009) and TC (p=0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse (p=0.006) and the greater number of relapses (p=0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new T2 lesions (p=0.002) and with increased brain atrophy (p<0.001) in patients with high LDL-C. CONCLUSIONS: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.<ovid:br /><ovid:br />Copyright &#xa9; 2013.

590    __

$a bohemika - dle Pubmed

650    02

$a dospělí $7 D000328

650    12

$a autoprotilátky $x krev $7 D001323

650    12

$a cholesterol $x krev $7 D002784

650    02

$a Cytomegalovirus $x izolace a purifikace $7 D003587

650    12

$a demyelinizační nemoci $x diagnóza $x krev $x virologie $7 D003711

650    12

$a progrese nemoci $7 D018450

650    12

$a infekce virem Epsteina-Barrové $x imunologie $x patologie $x virologie $7 D020031

650    02

$a virus Epsteinův-Barrové - jaderné antigeny $x krev $7 D019309

650    02

$a ženské pohlaví $7 D005260

650    12

$a Herpesviridae $x izolace a purifikace $7 D006564

650    12

$a virus Epsteinův-Barrové $x imunologie $x izolace a purifikace $7 D004854

650    02

$a lidé $7 D006801

650    02

$a longitudinální studie $7 D008137

650    02

$a mužské pohlaví $7 D008297

650    02

$a prospektivní studie $7 D011446

650    02

$a mladý dospělý $7 D055815

700    1_

$a Horáková, Dana $7 xx0076527

700    1_

$a Zivadinov R

700    1_

$a Tamano-Blanco M

700    1_

$a Badgett D

700    1_

$a Týblová, Michaela $7 xx0121850

700    1_

$a Vaněčková, Manuela, $d 1973- $7 mzk2007377403

700    1_

$a Seidl, Zdeněk, $d 1950- $7 mzk2004258727

700    1_

$a Krásenský, Jan $7 xx0096156

700    1_

$a Bergsland N

700    1_

$a Ramasamy DP

700    1_

$a Hagemeier J

700    1_

$a Kubala Havrdová, Eva, $d 1955- $7 nlk19990073204

700    1_

$a Ramanathan M

773    0_

$t Journal of Neuroimmunology $g Roč. 263, č. 1-2 (2013), s. 121-127 $p J Neuroimmunol $x 0165-5728 $w MED00002834

773    0_

$p J Neuroimmunol $g 263(1-2):121-7, 2013 Oct 15

910    __

$a ABA008 $y 4 $z 0

990    __

$a 20181023155040 $b ABA008

991    __

$a 20220411124857 $b ABA008

999    __

$a ok $b bmc $g 1345216 $s 1032725

BAS    __

$a 3

BMC    __

$a 2013 $b 263 $c 1-2 $d 121-127 $x MED00002834 $i 0165-5728 $m Journal of neuroimmunology

GRA    __

$a NT13237 $p MZ0

LZP    __

$a NLK 2018/lp